EPC Live Program 9.14.24

1. Which of the following tests provides the highest sensitivity and specificity for the diagnosis of bronchiectasis?*

Chest radiographComputed tomography with contrast (contrast CT)Chest magnetic resonance imaging (MRI)High resolution computed tomography (HRCT)Clinical examination and symptom scores

2. Which of the following airway clearance treatments is recommended against in patients with bronchiectasis?*

3. Which cell-type has been implicated in the inflammatory portion of the vicious vortex that has been used to describe the pathophysiology of bronchiectasis, and is targeted by dipeptidyl peptidase 1 (DPP1)?*

4. Brensocatib was shown in a Phase 2 clinical trial to significantly improve all of the following outcomes except:*

Sputum neutrophil elastaseMortalityTime to first bronchiectasis exacerbationQuality of life (St. George’s Respiratory Quotient)Rate of bronchiectasis exacerbations

5. A patient diagnosed with COPD who has an mMRC score of 2 with no exacerbating events would fall into which GOLD group? *

Group A (mild symptoms with low risk of exacerbations)Group B (moderate-to-severe symptoms with low risk of exacerbations)Group C (mild symptoms with high risk of exacerbations)Group E (any degree of symptoms with high risk of exacerbations)

6. In the Phase 3 BOREAS trial, treatment with dupilumab was associated with: *

No changes in COPD exacerbations but a favorable safety profileReduced COPD exacerbations in patients with high blood eosinophils but a higher incidence of respiratory infections compared to placeboReduced COPD exacerbations in patients regardless of blood eosinophil status and a favorable safety profileReduced COPD exacerbations and improved lung function in patients with high blood eosinophils and a favorable safety profile

7. Patient and clinician collaboration in developing a written COPD care plan has been shown to: *

Improve HRQoL onlyReduce respiratory-related hospital admissions onlyImprove HRQoL and reduce respiratory-related hospital admissionsHave no effect on COPD outcomes

Name*

First NameLast Name

Email*

example@example.com

What is your license?*

What is your specialty?*

PulmonologistPrimary CareOther

What is your practice setting?*

Private PracticeHospitalAcademicOther

Please rate the extent to which this activity met the following objectives:

Learning Objectives

	Poor	Fair	Good	Very Good	Excellent
Review the pathophysiology, diagnostic strategies, and unmet needs for patients with NCFBE
Analyze clinical trial data for NCFBE therapeutics including DPP1 inhibitor therapeutics
Apply current science to treatment plans to treat NCFBE regardless of baseline disease severity
Review emerging therapeutics for PAH, including the mode of action for activin signaling inhibitors
Analyze clinical trial data and clinical applications for activin signaling inhibitor therapeutics targeting higher risk patients with PAH
Recognize specific considerations for underserved populations and should effectively engage in collaboration with the healthcare team for optimal treatment of patients with PAH
Review newer maintenance therapies for COPD
Analyze clinical trial data for new and emerging COPD treatments including long-acting muscarinic antagonist (LAMA) therapeutics
Recognize barriers to care and unmet needs for patients with COPD and engage in patient education to improve treatment adherence

Please provide us with feedback regarding your experience at the activity:

	Poor	Fair	Good	Very Good	Excellent
Overall Program
Content
Usefulness

Please rate the faculty on their overall teaching ability:

	Poor	Fair	Good	Very Good	Excellent
Jeffrey Hoag, MD
Samantha Gillenwater, MD
Nick Hanania, MD

Do you feel this activity was fair balanced and free of commercial bias?

YesNo

If no, please explain:

This educational activity will result in a change in my role as a healthcare team member.

YesNoN/A

Based on your participation in this activity, choose the statement(s) that applies to how your role as a healthcare team member will change:

I gained new strategies/skills/information that my team can apply to practiceI plan to implement new strategies/skills/information in my practiceI will be more competent in my team’s management of patient careI will improve my communication with the healthcare team

What factors beyond clinical care that effect the health of your patients does your team experience?

Date

Attestation: This activity is certified for a maximum of 1.5 AMA PRA Category 1 Credits™.

I participated in this activity and claim _______ credit(s).*

PRE-TEST QUESTIONNAIRE

POST-TEST ASSESSMENT